Does recombinant growth hormone improve adult height in children with chronic renal failure?

2001 ◽  
Vol 21 (5) ◽  
pp. 490-497 ◽  
Author(s):  
Dieter Haffner ◽  
Franz Schaefer
Keyword(s):  
Growth Hormone ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Adult Height ◽  
Recombinant Growth Hormone

Accelerated growth in short children with chronic renal failure treated with both strict dietary therapy and recombinant growth hormone

1992 ◽  
Vol 6 (5) ◽  
pp. 451-458 ◽  
Author(s):  
Margaret J. van Renen ◽  
Russell J. Hogg ◽  
Annabel L. Sweeney ◽  
Paul H. Henning ◽  
James L. Penfold ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Dietary Therapy ◽  
Recombinant Growth Hormone ◽  
Short Children ◽  
Accelerated Growth

Effect of Growth Hormone Treatment on the Adult Height of Children with Chronic Renal Failure

2000 ◽  
Vol 343 (13) ◽  
pp. 923-930 ◽  
Author(s):  
Dieter Haffner ◽  
Franz Schaefer ◽  
Richard Nissel ◽  
Elke Wühl ◽  
Burkhard Tönshoff ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Adult Height ◽  
Growth Hormone Treatment ◽  
Hormone Treatment

scholarly journals Human Growth Hormone (GH) Stimulates Erythropoietin (EPO) Secretion in Anemic Patients with Chronic Renal Failure (CRF)

1994 ◽  
Vol 3 (Supple5) ◽  
pp. 192-194
Author(s):  
Motoi Sohmiya ◽  
Hong-Yi Hu ◽  
Junko Tanaka ◽  
Kimiko Ishikawa ◽  
Yoshio Murakami ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Human Growth Hormone ◽  
Human Growth

Impaired prolactin response to arginine infusion and insulin hypoglycaemia in chronic renal failure

1983 ◽  
Vol 102 (4) ◽  
pp. 486-491 ◽  
Author(s):  
O. Schmitz ◽  
J. Møller
Keyword(s):  
Growth Hormone ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Elevated Level ◽  
Matched Control ◽  
Chronic Haemodialysis ◽  
Arginine Infusion ◽  
Pituitary Dysfunction ◽  
Prolactin Response ◽  
Insight Into

Abstract. The elevated level of circulating prolactin present in the majority of uraemic patients on chronic haemodialysis is primarily due to hypothalamic pituitary dysfunction. So far this defect has been illustrated by demonstration of a blunted prolactin response to TRH and failure of l-dopa to suppress prolactin levels. In the present study two powerful prolactin and growth hormone stimuli, namely iv arginine infusion and insulin hypoglycaemia were applied in a group of uraemic patients on chronic haemodialysis and in age matched control subjects. The prolactin increments to arginine infusion (4.4 ± 1.2 ng/ml vs 17.6 ± 4.6 ng/ml, mean ± se) and to insulin hypoglycaemia (7.9 ± 1.7 ng/ml vs 31.5 ± 5.4 ng/ml) were significantly suppressed in the uraemic patients compared to the controls (P < 0.05). In contradistinction the growth hormone rise provoked by the tests were similar in the two groups. Our results provide further insight into the hypothalamic pituitary derangement in uraemic patients and confirm the presumption of an insensitivity of the lactotrophs to stimulation in uraemic patients.

Long Term Experience with Growth Hormone Treatment in Children with Chronic Renal Failure

1999 ◽  
Vol 19 (2_suppl) ◽  
pp. 467-472 ◽  
Author(s):  
Franz Schaefer ◽  
Dieter Haffner ◽  
Elke Wühl ◽  
Otto Mehls
Keyword(s):  
Growth Hormone ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Final Height ◽  
Recombinant Human Growth Hormone ◽  
Growth Failure ◽  
Skeletal Maturation ◽  
Height Velocity ◽  
Benign Intracranial Hypertension

After a decade of experience with recombinant human growth hormone (rhGH) in children with chronic renal failure (CRF), the long-term efficacy and safety of the drug is now established. In prepubertal children, partial catch-up growth is achieved during the first three treatment years, followed by sustained percentile-parallel growth. Discontinuation of rhGH treatment results in catch-down growth in 75% of patients. Treatment efficacy is inversely correlated with age and baseline height velocity, and positively influenced by genetic target height and residual renal function. Skeletal maturation is not accelerated, suggesting a true increase in final height potential. Side effects are limited to a stimulation of insulin secretion, which is not associated with changes in glucose tolerance, and occasional cases of benign intracranial hypertension. In summary, the advent of rhGH has opened a new era in the management of growth failure in CRF. Available evidence suggests that treatment should start in early childhood and early in the course of renal failure, and should be continued at least until renal transplantation. It remains to be seen whether the beneficial effect of rhGH on height observed during the prepubertal period will result in an eventual increase in adult height.

Sign in / Sign up

Export Citation Format

Share Document